A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 124-133

  Stearns, Vered ^a,b   Singh, Baljit ^a   Tsangaris, Theodore ^a   Crawford, Jeanette G ^a   Novielli, Antonella ^a   Ellis, Mathew J ^a   Isaacs, Claudine ^a   Pennanen, Marie ^a   Tibery, Cecilia ^a   Farhad, Ahmad ^a   Slack, Rebecca ^a   Hayes, Daniel F ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; ERYTHROPOIETIN; ESTROGEN RECEPTOR; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; NEUTROPENIA; ONCOGENE NEU; PERIPHERAL NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; APOPTOSIS; BIOPSY; BREAST NEOPLASMS; CELL DIVISION; CLINICAL TRIALS; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PILOT PROJECTS; RANDOM ALLOCATION; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 12244287617     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Peto, R., Boreham, J., Clarke, M., Davies, C., and Beral, V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet, 355: 1822, 2000.
2. Fisher, B., and Mamounas, E. Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer. J. Clin. Oncol., 13: 537-540, 1995.
3. Wolff, A. C., and Davidson, N. E. Primary systemic therapy in operable breast cancer. J. Clin. Oncol., 18: 1558-1569, 2000.
4. Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., Margolese, R. G., Cruz, A. B., Jr., Hoehn, J. L., Lees, A. W., Dimitrov, N. V., and Bear, H. D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol., 16: 2672-2685, 1998.
5. Feldman, L. D., Hortobagyi, G. N., Buzdar, A. U., Ames, F. C., and Blumenschein, G. R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res., 46: 2578-2581, 1986.
6. Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., Buchholz, T. A., Ross, M. I., McNeese, M. D., Buzdar, A. U., Hortobagyi, G. N., and Singletary, S. E. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol., 17: 460-469, 1999.
7. Ellis, P. A., Smith, I. E., McCarthy, K., Detre, S., Salter, J., and Dowsett, M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet, 349: 849, 1997.
8. Chang, J., Powles, T. J., Allred, D. C., Ashley, S. E., Clark, G. M., Makris, A., Assersohn, L., Gregory, R. K., Osborne, C. K., and Dowsett, M. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J. Clin. Oncol., 17: 3058-3063, 1999.
9. Dowsett, M., Archer, C., Assersohn, L., Gregory, R. K., Ellis, P. A., Salter, J., Chang, J., Mainwaring, P., Boeddinghaus, I., Johnston, S. R., Powles, T. J., and Smith, I. E. Clinical studies of apoptosis and proliferation in breast cancer. Endocr. Relat. Cancer, 6: 25-28, 1999.
10. Ellis, M., Hayes, D. F., and Lippman, M. E. Treatment of metastatic disease. In: J. Harris, M. Lippman, M. Morrow, and C. K. Osborne (eds.), Diseases of the Breast, Ed. 2, pp. 749-798. Philadelphia: Lippincott-Raven, 2000.
11. Sledge, G., Neuberg, D., Ingle, J., Martino, S., and Wood, W. Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first line therapy for metastatic breast cancer: An Intergroup trial. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 1a, 1997.
12. Seidman, A. D., Reichman, B. S., Crown, J. P., Yao, T. J., Currie, V., Hakes, T. B., Hudis, C. A., Gilewski, T. A., Baselga, J., Forsythe, P., and et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J. Clin. Oncol., 13: 1152-1159, 1995.
13. Hudis, C., Fornier, M., Riccio, L., Lebwohl, D., Crown, J., Gilewski, T., Surbone, A., Currie, V., Seidman, A., Reichman, B., Moynahan, M., Raptis, G., Sklarin, N., Theodoulou, M., Weiselberg, L., Salvaggio, R., Panageas, K. S., Yao, T. J., and Norton, L. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J. Clin. Oncol., 17: 1118-1126, 1999.
14. Fountzilas, G., Papadimitriou, C., Dafni, U., Bafaloukos, D., Skarlos, D., Moulopoulos, L. A., Razis, E., Kalofonos, H. P., Aravantinos, G., Briassoulis, E., Papakostas, P., Abela, K., Gogas, E., Kosmidis, P., Pavlidis, N., and Dimopoulos, M. A. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. J. Clin. Oncol., 19: 2232-2239, 2001.
15. Brown, W. B., Lovato, J., and Rundell, B. RANLST software. Houston, TX: The University of Texas, M. D. Anderson Cancer Center, Department of Biomathematics (bwb@odin.mda.uth.tmc.edu), 1992.
16. Fisher, B., Anderson, S., Wickerham, D., DeCillis, A., Dimitrov, N., Mamounas, E., Wolmark, N., Pugh, R., Atkins, J., Meyers, F., Abramson, N., Wolter, J., Bornstein, R., Levy, L., Romond, E., Caggian, V., Grimaldi, M., Jochimsen, P., and Deckers, P. Increased intensification and total dose of cyclohosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from NSABP B-22. J. Clin. Oncol., 15: 1858-1869, 1997.
17. Fisher, B., Anderson, S., DeCillis, A., Dimitrov, N., Atkins, J. N., Fehrenbacher, L., Henry, P. H., Romond, E. H., Lanier, K. S., Davila, E., Kardinal, C. G., Laufman, L., Pierce, H. I., Abramson, N., Keller, A. M., Hamm, J. T., Wickerham, D. L., Begovic, M., Tan-Chiu, E., Tian, W., and Wolmark, N. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J. Clin. Oncol., 17: 3374-3388, 1999.
18. Henderson, I. C., Berry, D., Demetri, G., Cirrincione, C., Goldstein, L., Martino, S., Ingle, J., Cooper, M., Canellos, G., Borden, E., Fleming, G., Holland, J., Graziano, S., Carpenter, J., Muss, H., and Norton, L. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 101a, 1998.
19. Winer, E., Berry, D., Duggan, D., Henderson, I. C., Cirrincione, C., Cooper, R., and Norton, L. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 101a, 1998.
20. Monfardini, S., Brunner, K., and Crowther, D. Evaluation of the cancer patient and the response to treatment. In: UICC-Manual of Adult and Pediatric Medical Oncology, pp. 22-38. Berlin, Germany: Springer, 1987.
21. Hollander, M., and Wolfe, D. A. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973.
22. Scheffe, H. The Analysis of Variance, pp. 55-87. New York: John Wiley & Sons, Inc., 1959.
23. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
24. Symmans, W. F., Volm, M. D., Shapiro, R. L., Perkins, A. B., Kim, A. Y., Demaria, S., Yee, H. T., McMullen, H., Oratz, R., Klein, P., Formenti, S. C., and Muggia, F. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin. Cancer Res., 6: 4610-4617, 2000.
25. Makris, A., Powles, T. J., Allred, D. C., Ashley, S. E., Trott, P. A., Ormerod, M. G., Titley, J. C., and Dowsett, M. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res. Treat., 53: 51-59, 1999.
26. Lippman, M. E., Allegra, J. C., Thompson, E. B., Simon, R., Barlock, A., Green, L., Huff, K. K., Do, H. M. T., Aitken, S. C., and Warren, R. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med., 298: 1223-1228, 1978.
27. Colleoni, M., Minchella, I., Mazzarol, G., Nole, F., Peruzzotti, G., Rocca, A., Viale, G., Orlando, L., Ferretti, G., Curigliano, G., Veronesi, P., Intra, M., and Goldhirsch, A. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann. Oncol., 11: 1057-1059, 2000.
28. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351: 1451-1467, 1998.
29. Yamauchi, H., Stearns, V., and Hayes, D. F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol., 19: 2334-2356, 2001.
30. Konecny, G., Thomssen, M., Pegram, M., Luck, H., Untch, M., Pauletti, G., Dandekar, U., Ramos, L., Kuhn, W., Eidtmann, H., DuBois, A., Olbricht, S., Steinfeld, D., Moebus, V., Minckwitz, G., and Slamon, D. J. HEr-2/neu gene amplification and response to paclitaxel in patients with metatatic breast cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 23a, 2001.
31. Kandioler-Eckersberger, D., Ludwig, C., Rudas, M., Kappel, S., Janschek, E., Wenzel, C., Schlagbauer-Wadl, H., Mittlbock, M., Gnant, M., Steger, G., and Jakesz, R. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res., 6: 50-56, 2000.
32. Elledge, R. M., Green, S., Howes, L., Clark, G. M., Berardo, M.,Allred, D. C., Pugh, R., Ciocca, D., Ravdin, P., O'Sullivan, J., Rivkin, S., Martino, S., and Osborne, C. K. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J. Clin. Oncol., 15: 1916-1922, 1997.